



## **PRESS RELEASE**

**July 28, 2010 – Leuven, Belgium**

### **FORMAC strengthens management with appointment of CSO and COO**

#### **FILIP KIEKENS, Chief Scientific Officer**

FORMAC Pharmaceuticals N.V., a Belgian-based drug delivery and development company, today announced that **Filip Kiekens** will become the company's new Chief Scientific Officer.

Dr. Filip Kiekens joins FORMAC from the Pharmaceutical Development Division of Johnson & Johnson (JANSSEN Pharmaceutica NV), where he led early and late development projects with increasing responsibilities. During his extensive research and development of complex active compounds, he was recognized with the JNJ Standards of Leadership award and the Philip B. Hofmann Research Scientist Award. For the successful development of INTELENCE®, a novel HIV drug, he was awarded the Johnson Medal, the most prestigious award given to scientists and technologists in Johnson & Johnson. As one of the Flanders District of Creativity Fellows, Filip merges his scientific passion of formulating complex molecules with his entrepreneurial spirit into business opportunities.

Jan Rosier, CEO of FORMAC Pharmaceuticals, says: "We are extremely pleased to have Filip in our team because of his expertise in solving drug delivery problems for insoluble drugs. In particular his expertise in solid dispersion technologies and his know-how in introducing these technologies in full scale manufacturing settings is of particular importance for FORMAC".

Filip graduated as a pharmacist in 1995 and holds a Ph.D. in Pharmaceutical Technology from the University of Ghent, Belgium.

#### **LAURENT SCHUELLER, Chief Operating Officer**

FORMAC Pharmaceuticals N.V., also announced that **Laurent Schueller** will become the company's new Chief Operating Officer.

Dr. Laurent Schueller joins FORMAC Pharmaceuticals N.V. from Tibotec, where he was Chemical & Pharmaceutical Team Leader for the development of 2 late stage programs for the treatment of tuberculosis (TMC207) and HIV (TMC114). He was also involved in defining outsourcing strategies for the pharmaceutical development projects of Johnson and Johnson. Prior to his responsibilities in drug development, Laurent was responsible for budget management & control of a diverse portfolio of early and late development drugs. At FORMAC, Laurent will be responsible for the drug development programs and the associated operational activities.

Laurent graduated as a Pharmacist from the University of Strasbourg, France and holds a Ph.D. in Pharmaceutical Technology from the University of London, UK. He obtained his MBA from the Vlerick Business School in Belgium.

**About FORMAC:**

FORMAC is an emerging pharmaceutical R&D company engaged in oral drug delivery and development. The company has developed four proprietary drug delivery technologies which it uses as a starting-point for the in-house development of improved drug delivery forms of marketed drugs. In addition, FORMAC licenses its unique drug delivery technologies to pharmaceutical companies for formulation development of pre-clinical drug candidates and for line-extension developments. FORMAC was created in October 2007 as a spin-off from the University of Leuven, Belgium.

**For more information:**

Jan Rosier, Ph.D.

CEO, FORMAC Pharmaceuticals NV

Phone +32 476 205 810